查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
尿素循環障礙治療市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按酶缺乏類型、治療類型、給藥途徑、配銷通路、公司和地區細分
市場調查報告書
商品編碼
1321050

尿素循環障礙治療市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按酶缺乏類型、治療類型、給藥途徑、配銷通路、公司和地區細分

Urea Cycle Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Enzyme Deficiency Type, By Treatment Type, By Route of Administration, By Distribution Channel, By Company, and By Region
出版日期: | 出版商: TechSci Research | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計全球尿素循環障礙治療市場在2023-2027年預測期內將出現令人印象深刻的成長。主要因素包括尿素循環障礙的日益流行，以及廣泛的研究和開發推動全球市場的成長。尿素循環障礙（UCD）是一組構成門靜脈周圍肝細胞尿素循環的遺傳缺陷。支持市場成長的其他因素包括政府對研發活動的投資增加、主要參與者的主動性增加、大眾意識的提高、更好的醫療服務的存在以及越來越多的創新診斷方法。

人群中尿素循環障礙的患病率上升

尿素循環障礙的日益流行可能會推動全球市場的成長。根據美國疾病控制與預防中心 (CDC) 發布的報告，預計每 8500 名新生兒中就有 1 人會出現尿素循環障礙。由於許多病例尚未確診，患有該疾病的新生兒在沒有得到完整診斷的情況下死亡；確切的數位仍然未知。據推測，高達20%的嬰兒猝死綜合症 (SIDS) 病例可能歸因於未確診的先天性代謝缺陷，例如尿素循環障礙，預計這將推動尿素循環障礙治療市場的發展。

提高患者的主動性和意識

在過去的幾年裡，各國政府和私人組織一直在採取多項措施來促進市場的成長。不斷增加的舉措，例如對研發的大量投資、提高認知計劃、廣泛的研究活動和臨床試驗以及監管機構批准的便利性是市場的支撐因素。例如，2017年，Mead Johnson Nutrition Company (MJN) 宣布與Reckitt Benckiser Group plc (RB) 合併。Mead Johnson 現為 RB 旗下子公司，將其全球知名品牌（用於尿素循環障礙飲食管理的 Enfa 和 Nutramigen）涵蓋 RB 的消費者健康產品組合，鞏固了其全球地位。同樣，2017年，Horizo​​n Pharma plc 推出了 UCD in Common，這是一項針對尿素循環障礙患者的計劃，為 UCD 患者、其家人和醫療保健專家提供教育、支持和互動資源。

市場細分

全球尿素循環障礙治療市場分為酶缺乏類型、治療類型、給藥途徑、配銷通路和公司。根據酶缺乏類型，市場分為氨甲醯磷酸合成酶（CPS1）、N-乙醯谷氨酸合成酶（NAGS）、鳥氨酸轉氨甲醯酶（OTC缺乏）、精氨琥珀酸合成酶（ AS）、精氨琥珀酸裂解酶（AL或ASA裂解酶）、和精氨酸酶（AG）。根據治療類型，市場分為氨基酸配方、苯丁酸、苯甲酸鈉等。根據給藥途徑，市場分為口服和靜脈注射。根據配銷通路，市場分為醫院藥房、零售藥房和網路藥房。就國家而言，由於美國尿素循環疾病病例數量不斷增加，預計在預測期內美國將是一個利潤豐厚的市場。

市場參與者

Bausch Health Companies Inc.、Recordati Rare Diseases、Eurocept Pharmaceuticals Holding (Lucane Pharma SA)、Acer Therapeutics、Ultragenyx Pharmaceutical、Aeglea BioTherapeutics、Arcturus Therapeutics, Inc.、Orpharma Pty Ltd.、Selecta Biosciences, Inc和 Abbott Laboratories, Inc.是市場上營運的一些領先公司。

可用的客製化

根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。本報告可以使用以下自定義選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第1章：產品概述

第2章：研究方法

第3章：COVID-19 對全球尿素循環障礙治療市場的影響

第4章：客戶之聲

第5章：執行摘要

第6章：全球尿素循環障礙治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按酶缺乏類型（氨甲醯磷酸合成酶(CPS1)、N-乙醯谷氨酸合成酶(NAGS)、鳥氨酸轉氨甲醯酶（OTC 缺乏）、精氨基琥珀酸合成酶(AS)、精氨基琥珀酸裂解酶（AL 或ASA 裂解酶）、精氨酸酶(AG)）
    • 按治療類型（氨基酸配方、丁酸苯酯、苯甲酸鈉等）
    • 按給藥途徑（口服與靜脈注射）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按公司分類 (2021)
    • 按地區
  • 市場地圖

第7章：北美尿素循環障礙治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按酶缺乏類型
    • 按治療類型
    • 按給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第8章：歐洲尿素循環障礙治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按酶缺乏類型
    • 按治療類型
    • 按給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章：亞太地區尿素循環障礙治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按酶缺乏類型
    • 按治療類型
    • 按給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第10章：南美尿素循環障礙治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按酶缺乏類型
    • 按治療類型
    • 按給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章：中東和非洲尿素循環障礙治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按酶缺乏類型
    • 按治療類型
    • 按給藥途徑
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非尿素循環障礙治療
    • 沙烏地阿拉伯尿素循環障礙治療
    • 阿拉伯聯合大公國尿素循環障礙治療

第12章：市場動態

  • 促進因素
  • 挑戰

第13章：市場趨勢與發展

第14章：競爭格局

  • Bausch Health Companies Inc.
  • Recordati Rare Diseases
  • Eurocept Pharmaceuticals Holding (Lucane Pharma SA)
  • Acer Therapeutics
  • Ultragenyx Pharmaceutical
  • Aeglea BioTherapeutics
  • Arcturus Therapeutics, Inc.
  • Orpharma Pty Ltd.
  • Selecta Biosciences, Inc
  • Abbott Laboratories, Inc.

第15章：戰略建議

簡介目錄
Product Code: 12980

The global urea cycle disorders treatment market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include the increasing prevalence of urea cycle disorder, and extensive research and development are driving the growth of the market globally. Urea cycle disorders (UCDs) are a group of genetic defects that constitute the urea cycle in the periportal liver cells. The other factors supporting the market's growth are rising investments in research and development activities by the government, increasing initiatives by key players, rising awareness among the masses, the presence of better healthcare services, and a growing number of innovative diagnostic approaches.

Rising Prevalence of urea cycle disorders among the Population

The growing prevalence of urea cycle disorders is likely to propel the growth of the market globally. According to reports published by the Centers for Disease Control and Prevention (CDC), the projected occurrence of urea cycle disorders is 1 in 8500 births. Owing to the many cases which remain undiagnosed and the newborns with the disorders die without a complete diagnosis; the exact numbers remain unknown. It is assumed that up to 20% of Sudden Infant Death Syndrome (SIDS) cases may be ascribed to an undiagnosed inborn error of metabolism, such as a urea cycle disorder which is anticipated to impel the urea cycle disorders treatment market.

Increasing Initiatives and Awareness Among Patients

Over the past few years, governments of different nations and private organizations have been taking several steps to bolster the growth of the market. Rising initiatives such as heavy investments in research and development, increase in awareness programs, extensive research activities and clinical trials, and ease in approvals by the regulatory bodies are the supporting factors for the market. For instance, in 2017, Mead Johnson Nutrition Company (MJN) declared its merger with Reckitt Benckiser Group plc (RB). Mead Johnson, now a division of RB, included its globally recognized brands, incorporating Enfa and Nutramigen, which are used in the dietary management of urea cycle disorder, to RB's consumer health portfolio, thus bolstering its position globally. Similarly, in 2017, Horizon Pharma plc launched UCD in Common, an initiative for individuals suffering from urea cycle disorder, to offer educational, supportive, and interactive resources to the patients residing with UCD, their families, and healthcare specialists.

Market Segmentation

The global urea cycle disorders treatment market is segmented into enzyme deficiency type, treatment type, route of administration, distribution channel, and company. Based on enzyme deficiency type, the market is divided into carbamyl phosphate synthetase (CPS1), N-acetyl glutamate synthetase (NAGS), ornithine transcarbamylase (OTC deficiency), argininosuccinic acid synthetase (AS), argininosuccinate lyase (AL or ASA lyase), and arginase (AG). Based on treatment type, the market is divided into amino acid formulas, phenylbutyrate, sodium benzoate, and others. Based on the route of administration, the market is divided into oral and intravenous. Based on distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising number of cases of urea cycle diseases in the country.

Market Players

Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc, and Abbott Laboratories, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global urea cycle disorders treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type:

  • Carbamyl Phosphate Synthetase (CPS1)
  • N-Acetylglutamate Synthetase (NAGS)
  • Ornithine Transcarbamylase (OTC Deficiency)
  • Argininosuccinic Acid Synthetase (AS)
  • Argininosuccinate Lyase (AL or ASA Lyase)
  • Arginase (AG)

Urea Cycle Disorders Treatment Market, By Treatment Type:

  • Amino Acid Formulas
  • Phenylbutyrate
  • Sodium Benzoate
  • Others

Urea Cycle Disorders Treatment Market, By Route of Administration:

  • Oral
  • Intravenous

Urea Cycle Disorders Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Urea Cycle Disorders Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Urea Cycle Disorders Treatment Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Urea Cycle Disorders Treatment Market

4. Voice of Customer

5. Executive Summary

6. Global Urea Cycle Disorders Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG))
    • 6.2.2. By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others)
    • 6.2.3. By Route of Administration (Oral v/s Intravenous)
    • 6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.5. By Company (2021)
    • 6.2.6. By Region
  • 6.3. Market Map

7. North America Urea Cycle Disorders Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Enzyme Deficiency Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Urea Cycle Disorders Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Enzyme Deficiency Type
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Mexico Urea Cycle Disorders Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Enzyme Deficiency Type
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. Canada Urea Cycle Disorders Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Enzyme Deficiency Type
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel

8. Europe Urea Cycle Disorders Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Enzyme Deficiency Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Urea Cycle Disorders Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Enzyme Deficiency Type
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. Germany Urea Cycle Disorders Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Enzyme Deficiency Type
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. United Kingdom Urea Cycle Disorders Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Enzyme Deficiency Type
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. Italy Urea Cycle Disorders Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Enzyme Deficiency Type
        • 8.3.4.2.2. By Treatment Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Spain Urea Cycle Disorders Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Enzyme Deficiency Type
        • 8.3.5.2.2. By Treatment Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. Asia-Pacific Urea Cycle Disorders Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Enzyme Deficiency Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Urea Cycle Disorders Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Enzyme Deficiency Type
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. India Urea Cycle Disorders Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Enzyme Deficiency Type
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Japan Urea Cycle Disorders Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Enzyme Deficiency Type
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel
    • 9.3.4. South Korea Urea Cycle Disorders Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Enzyme Deficiency Type
        • 9.3.4.2.2. By Treatment Type
        • 9.3.4.2.3. By Route of Administration
        • 9.3.4.2.4. By Distribution Channel
    • 9.3.5. Australia Urea Cycle Disorders Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Enzyme Deficiency Type
        • 9.3.5.2.2. By Treatment Type
        • 9.3.5.2.3. By Route of Administration
        • 9.3.5.2.4. By Distribution Channel

10. South America Urea Cycle Disorders Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Enzyme Deficiency Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Urea Cycle Disorders Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Enzyme Deficiency Type
        • 10.3.1.2.2. By Treatment Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Argentina Urea Cycle Disorders Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Enzyme Deficiency Type
        • 10.3.2.2.2. By Treatment Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Colombia Urea Cycle Disorders Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Enzyme Deficiency Type
        • 10.3.3.2.2. By Treatment Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Middle East and Africa Urea Cycle Disorders Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Enzyme Deficiency Type
    • 11.2.2. By Treatment Type
    • 11.2.3. By Route of Administration
    • 11.2.4. By Distribution Channel
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Urea Cycle Disorders Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Enzyme Deficiency Type
        • 11.3.1.2.2. By Treatment Type
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By Distribution Channel
    • 11.3.2. Saudi Arabia Urea Cycle Disorders Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Enzyme Deficiency Type
        • 11.3.2.2.2. By Treatment Type
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By Distribution Channel
    • 11.3.3. UAE Urea Cycle Disorders Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Enzyme Deficiency Type
        • 11.3.3.2.2. By Treatment Type
        • 11.3.3.2.3. By Route of Administration
        • 11.3.3.2.4. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Bausch Health Companies Inc.
  • 14.2. Recordati Rare Diseases
  • 14.3. Eurocept Pharmaceuticals Holding (Lucane Pharma SA)
  • 14.4. Acer Therapeutics
  • 14.5. Ultragenyx Pharmaceutical
  • 14.6. Aeglea BioTherapeutics
  • 14.7. Arcturus Therapeutics, Inc.
  • 14.8. Orpharma Pty Ltd.
  • 14.9. Selecta Biosciences, Inc
  • 14.10. Abbott Laboratories, Inc.

15. Strategic Recommendations